Molecular biomarkers impact survival after neoadjuvant chemoradiation in locally advanced soft tissue sarcoma patients
Locally advanced, marginally resectable soft tissue sarcomas (STS) are frequently treated with multimodal neoadjuvant strategies to enable limb-sparing, R0 resection. However, pathological response (PR) to neoadjuvant chemoradiation is heterogeneous, and robust molecular predictors of response are lacking. We performed comprehensive DNA/RNA profiling to identify genomic correlates of PR and clinical outcomes in a real-world cohort treated with a uniform neoadjuvant chemoradiation regimen.
Locally advanced, marginally resectable soft tissue sarcomas (STS) are frequently treated with multimodal neoadjuvant strategies to enable limb-sparing, R0 resection. However, pathological response (PR) to neoadjuvant chemoradiation is heterogeneous, and robust molecular predictors of response are lacking. We performed comprehensive DNA/RNA profiling to identify genomic correlates of PR and clinical outcomes in a real-world cohort treated with a uniform neoadjuvant chemoradiation regimen.
University of Warsaw